Image Analysis Group opens Cambridge office to expand U.S. reach

Image Analysis Group opened a new U.S. office in Cambridge, Massachusetts, this summer to deepen ties with biotech and pharma companies in the Boston life-sciences hub. The move is designed to support imaging-driven clinical trials faster and could add jobs across operations, data science, regulatory support and business development over the next 12 to 24 months.

Why it matters: - Image Analysis Group’s new Cambridge office puts the clinical-trial imaging specialist closer to one of the world’s most concentrated biotech markets. - The location is meant to speed support for sponsors and CROs running imaging-heavy trials in oncology, immunology, neuro-oncology, radiopharmaceuticals, rheumatic disease and metabolic disease. - The expansion also signals continued U.S. growth for the London-based iCRO as more drug development work moves through Boston’s life-sciences ecosystem.

What happened: - Image Analysis Group opened a new U.S. office in Cambridge, Massachusetts, this summer. - The office sits in the Boston area, near biotech companies, pharmaceutical partners, academic institutions and clinical research leaders. - The move brings IAG’s operations and business development teams closer to clients shaping clinical development. - The company is using the office to strengthen its support for sponsors and CROs.

The details: - The Cambridge office is intended to support end-to-end imaging services. - Those services include trial design consultation, imaging protocol optimization, centralized image analysis and regulatory-compliant data delivery. - IAG said the office will help it respond more quickly to emerging clinical trial needs in the region. - Planned hiring over the next 12 to 24 months covers clinical imaging operations, data science, regulatory support and business development. - IAG supports clinical trials across North America, Europe and Asia-Pacific. - The company works with sponsors and CROs on global, multi-center studies. - IAG says its operational hubs and regulatory experience help standardize imaging protocols and centralize data harmonization. - The company was founded in 2007 and is headquartered in London. - IAG positions itself as a global specialist imaging clinical research organization. - Its proprietary DYNAMIKA platform combines AI-driven image analysis, centralized quality control, regulatory-compliant reporting and real-time trial oversight. - IAG’s teams are based across the UK, U.S., EU and India. - The company’s disease focus includes oncology, inflammatory disease, musculoskeletal disease, cardiometabolic disease and rare disease.

Between the lines: - Boston remains a strategic landing spot for life-sciences vendors because proximity to sponsors can shorten feedback loops during early trial design and regulatory planning. - IAG’s pitch is that local presence improves responsiveness, while its global operating model supports studies that cross borders and regulatory regimes. - The company is also leaning into the growing demand for AI-enabled imaging analytics in complex clinical trials.

What's next: - IAG expects the Cambridge office to support more direct collaboration with biotech and pharma teams running Phase I through Phase III programs. - The office should help the company expand local partnerships and accelerate development timelines for imaging-driven studies. - New hires over the next two years will likely deepen the office’s operational footprint in the Boston market.

The bottom line: - IAG is betting that a Boston-area presence will make it more useful to U.S. drug developers while reinforcing its global imaging business.